| DB ID | MyCo_7049 |
| Title | KL-6 as a predictor of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) and mortality in critically ill COVID-19 patients: A single-center retrospective cohort study |
| Year | 2025 |
| PMID | 40194943 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | COVID-19 |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Institutional Review Board (IRB) of Samsung Changwon Hospital (IRB number: SCMC 2022-06-016) and conducted in compliance with the princi- ples outlined in the Declaration of Helsinki. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | KL-6 |
| Biomarker Full Name | Krebs von den Lungen-6 |
| Biomarker Type | Predictive |
| Biomolecule | Protein |
| Geographical Location | Republic of Korea |
| Cohort | 238 eligible study participants were included in the study. |
| Cohort No. | 238 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Immunological assay |
| Analysis Method | Turbidimetric immunoassay |
| ELISA kits | None |
| Assay Data | Turbidimetric immunoassay (Nanopia KL-6, Sekisui Medical, Tokyo, Japan) |
| Validation Techniques used | Turbidimetric immunoassay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
